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Abstract
BACKGROUND
The utility of novel oral soluble guanylate cyclase (sGC) stimulators (vericiguat
and riociguat), in patients with reduced or preserved ejection fraction heart failure
(HFrEF/HFpEF) is currently unclear.
AIM
To determine the efficacy and safety of sGC stimulators in HF patients.
METHODS
Multiple databases were searched to identify relevant randomized controlled
trials (RCTs). Data on the safety and efficacy of sGC stimulators were compared
using relative risk ratio (RR) on a random effect model.
RESULTS
Six RCTs, comprising 5604 patients (2801 in sGC stimulator group and 2803
placebo group) were included. The primary endpoint (a composite of
cardiovascular mortality and first HF-related hospitalization) was significantly
reduced in patients receiving sGC stimulators compared to placebo [RR 0.92, 95%
confidence interval (CI): 0.85-0.99, P = 0.02]. The incidence of total HF-related
hospitalizations were also lower in sGC group (RR 0.91, 95%CI: 0.86-0.96, P =
0.0009), however, sGC stimulators had no impact on all-cause mortality (RR 0.96,
95%CI: 0.86-1.07, P = 0.45) or cardiovascular mortality (RR 0.94, 95%CI: 0.83-1.06,
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P= 0.29). The overall safety endpoint (a composite of hypotension and syncope)
was also similar between the two groups (RR 1.50, 95%CI: 0.93-2.42, P = 0.10). By
contrast, a stratified subgroup analysis adjusted by type of sGC stimulator and HF
(vericiguat vs riociguat and HFrEF vs HFpEF) showed near identical rates for all
safety and efficacy endpoints between the two groups at a mean follow-up of 19
wk. For the primary composite endpoint, the number needed to treat was 35, the
number needed to harm was 44.

Manuscript source: Unsolicited

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

CONCLUSION
The use of vericiguat and riociguat in conjunction with standard HF therapy,
shows no benefit in terms of decreasing HF-related hospitalizations or mortality.
Key Words: Vericiguat; Riociguat; Soluble guanylate cyclase; Heart failure; Guanylate
cyclase stimulator
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Core Tip: Recently soluble guanylate cyclase (sGC) stimulators (vericiguat and
riociguat) have emerged as a novel treatment for heart failure with reduced or
preserved ejection fraction. Data published in literature revealed no additional benefits
to guideline-based medical therapy in reducing incidence of heart failure
hospitalization and mortality with sGC stimulator use. Large scale studies are required
to determine the efficacy of sGC stimulators in patients with heart failure.
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INTRODUCTION
There are an estimated 6.5 million adults in the United States suffering from heart
failure (HF) with the disease accounting for nearly 1 in every 8 deaths[1] Approximately
1 million[2,3] HF-related hospitalizations (HHF) occur annually, accounting[4] for over
6.5 million hospital days and $37.2 billion in costs every year[1]. This economic burden
has risen dramatically over the past two decades, with the increasing prevalence of
risk factors for HF adding to new cases and better therapies adding to increased life
expectancy among HF patients[1].
Despite traditional pharmacologic management with beta-blockers, angiotensinconverting-enzyme inhibitors (ACEI) and mineralocorticoid receptor antagonists to
reduce HF exacerbations and mitigate clinical progression, overall prognosis remains
dismal[2]. This has led researchers to target alternative pathways involved in the
pathogenesis of HF, with promising research focusing on soluble guanylate cyclase
(sGC) and the natriuretic peptide system (NPS)[3,4].
Both pathways influence myocardial perfusion and ventricular function through
their common second messenger: Cyclic guanosine monophosphate (cGMP). The
therapeutic augmentation of NPS with a combination angiotensin receptor–neprilysin
inhibitor (sacubitril) has proven to be immensely beneficial, to the extent that the
pioneering PARADIGM trial was halted early given the clear benefits in terms
reducing mortality [risk ratio (RR) 0.84, 95% confidence interval (CI): 0.76-0.93, P <
0.001] and hospitalization (by 21%, P < 0.001) compared to ACEI alone[5]. However, the
use of conventional vasodilators (nitrites and nitrates) to achieve soluble GC activation
has met with more mixed results, with the development of tolerance, hypotension and
failure of treatment being reported[6]. These discouraging findings have been attributed
to a relative deficiency of sGC due to reduced nitric oxide (NO) bioavailability and
endothelial dysfunction in HF leading to impaired cyclic GMP generation[7].
Novel sGC stimulators (vericiguat and riociguat) have shown advances over
traditional vasodilators[6], by augmenting the cGMP signaling pathway, independent
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of NO and enhancing the effect of endogenous NO[2,8]. In contrast to the conventional
therapeutic approach of antagonizing counterregulatory neurohormonal pathways,
such as by phosphodiesterase inhibitors, or by addition of exogenous NO, sGC
stimulators sensitize soluble GC to endogenous NO, thereby potentially having more
efficacy for HF treatment[9].
In this regard, multiple clinical trials have attempted to explore the utility of
vericiguat and riociguat in patients with HF[2,8]. The VICTORIA (vericiguat Global
Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial recently
established that vericiguat in patients with HFrEF can reduce the risk of
cardiovascular mortality and HF-related hospitalizations[2]. These findings, however,
stand in contrast to previous trials that have not shown any consistent benefit with
sGC stimulators. The ambiguity of current literature and the absence of any definite
large-scale studies to determine the true merits of sGC stimulators in patients with HF,
motivated us to perform this meta-analysis.

MATERIALS AND METHODS
Search strategy and data extraction
The MEDLINE (PubMed, Ovid), Embase, Clinicaltrials.org and Cochrane databases
were queried with various combinations of medical subject headings (MeSH) to
identify relevant articles. There were no language or time restrictions placed.
Backward snowballing was performed to retrieve unidentified studies that were
missed on the initial search. The MeSH used included two subsets: One for HF using
the terms like “heart failure,” “HFrEF,” “HFpEF,” “CHF,” “cardiac failure,” and the
other for sGC using “guanylate cyclase stimulators,” “sGC,” “vericiguat,” and
“riociguat.” The two subsets of MeSH were combined in a 1:1 combination using
Boolean operators. Results from all possible combinations were downloaded into an
EndNote library. All randomized control trials (RCT) until March 31, 2020, comparing
the safety and efficacy of sGC in HF were evaluated for inclusion.
Patients with HFrEF and HFpEF [New York Heart Association (NYHA) class II-IV],
on optimal guideline-based medical therapy requiring hospitalization or outpatient
intravenous (IV) diuretics, were included in this study. Patients requiring IV inotropic
support, in acute decompensated HF or requiring mechanical device support were
excluded, so were patients using suboptimal doses of vericiguat (< 10 mg daily) or
riociguat (< 2 mg daily), nitrates, alternative sGC stimulators or PDE inhibitors.
The primary efficacy endpoint was a composite of the first hospitalization for HF
and death from cardiovascular causes. The secondary efficacy endpoints were the
components of the primary outcome, total HF-related hospitalizations, cardiovascular
and all-cause mortality. Safety endpoints included anemia, hypotension, syncope, and
a composite of the later two. A detailed search map and definition of outcomes are
given in the Supplementary Appendix.

Data and quality analysis
The statistical analysis was performed using the Cochran–Mantel–Haenszel test on a
random-effect model to calculate RR for the dichotomous outcomes of RCTs. The
probability value of P < 0.05 was considered statistically significant. The “test for
overall effect” was reported as the z value corroborating the inference from the 95%CI.
Subgroup analysis based on the choice of sGC stimulator and type of HF was also
performed. Higgins I-squared (I2) statistical model was used to assess variations in
outcomes of the included studies. I2 less than 40% corresponded to low heterogeneity.
Depending upon the strength of evidence for heterogeneity (P value from the chisquare χ2 analysis), I2 of 41 to 74% indicated moderate (P ≥ 0.05) or moderate to severe (
P ≤ 0.05) and I2 of 75% or higher suggested substantial heterogeneity. Publication bias
was illustrated graphically using a funnel plot. The methodological quality assessment
of the included RCTs was performed using the Cochrane collaboration tool for the
systematic review and meta-analysis, where each study was screened for five different
types of bias (selection, performance, detection, attrition, and reporting bias). All
statistical analysis was performed using the Cochrane Review Manager (RevMan)
version 5.3.

Quality of the included studies
The overall quality of the included RCTs was high (Figure 1). Due to adequate
randomization and allocation concealment, the risk of selection bias was low. The risk
of performance and detection bias were reduced with appropriate blinding of
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Figure 1 Summary and detailed methodological quality of the included studies. A: Summary of the included studies; B: Detailed methodological
quality of the included studies.

participants and outcomes, respectively. Similarly, reporting bias across all studies
was decreased due to an adequate description of the study results. The fact that most
RCTs used an “intention to treat model” or had a minimal loss at follow-up, the risk of
attrition bias was low.

RESULTS
Search results and study characteristics
The initial search revealed 1905 articles. After the removal of irrelevant and duplicate
items, 43 studies were selected for full-text review. Of these, 37 articles were excluded
based on our selection criteria, 6 articles (all RCTs) qualified for quantitative
analysis[2,8,10-13]. The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) flow diagram is shown in Figure 2.
A total of 5604 patients, 2801 in the sGC stimulator group, and 2803 in the placebo
group were included. The mean age of patients receiving sGC stimulator was 64 and
for the placebo group 62 years; comprising 59% and 57% male patients, respectively.
Three of the included trials used vericiguat (1.25, 2.5, 5, or 10 mg), and three RCTs
used riociguat (0.5, 1, or 2 mg) in the experimental arm. Baseline characteristics of
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Figure 2 Flow diagram of the included studies showing reasons for exclusion.

treatment and placebo groups were comparable. Use of the concomitant guidelinedirected HF medical therapy was also balanced between the two groups. The
VICTORIA and the (soluble guanylate cyclase stimulator in heart failure patients with
preserved and reduced EF) SOCRATES trials used vericiguat in HFrEF patients. These
patients had a mean EF of 29% and NYHA class III-IV. The median baseline Nterminal pro-B-type natriuretic peptide (NT-proBNP) levels were 2816 pg/mL and
3076 pg/mL, respectively. The SOCRATES-PRESERVED trial used the Kansas City
cardiomyopathy questionnaire-clinical summary score to gauge symptomatic
improvement in the HFpEF population. The DILATE-1 (acute hemodynamic effects of
riociguat in patients with pulmonary hypertension associated with diastolic heart
failure) investigated riociguat in the HFpEF population. The PAH-CHD (pulmonary
arterial hypertension after correction of congenital heart disease) trial included
younger patients with a mean 38 ± 15 years. The PAH-CHD and the LEPHT (left
ventricular systolic dysfunction associated with pulmonary hypertension) had 100%
and 97% of HF patients with NYHA II-III, respectively. The overall follow-up duration
ranged from 12-43 wk, with a mean follow up of 19 wk. The detailed baseline
characteristics, inclusion criteria, and definitions of outcomes are given in
Supplementary Tables 1-3, respectively.

Pooled analysis of overall studies
Pooled efficacy endpoints: Four studies comprising 5530 patients (2752 sGC
stimulator and 2778 placebo) compared the primary composite endpoint
(cardiovascular mortality plus first-time hospitalization) between the sGC stimulators
and the control group. At a mean follow-up of 21-wk, a significantly lower rate of the
primary endpoint was obtained with the use of sGC stimulator in HF patients (RR
0.92, 95%CI: 0.85-0.99, P = 0.02) (Figure 3A). Similarly, compared to placebo, the rate of
total HF-related hospitalizations was significantly lower (RR 0.91, 95%CI: 0.86-0.96, P =
0.000.9) in patients on sGC stimulators. However, the incidence of cardiovascular and
all-cause mortality remained identical in both groups at a mean follow up of 19-mo
(RR 0.94, 95%CI: 0.83-1.06, P = 0.29 and RR 0.96, 95%CI: 0.86-1.07, P = 0.45,
respectively) (Figure 3B). Six studies consisting of 5604 patients (2801 sGC stimulator
and 2803 placebo) contributed to the later comparison (Figure 4). There was no
heterogeneity among the outcomes of the included studies (I2 = 0%).
Pooled safety endpoints: Six studies comprising 5596 patients (2793 sGC stimulator
and 2803 placebo) were used to calculate the incidence of net adverse events of clinical
interest (NAECI) (a composite of hypotension and syncope). The rate of NAECI was
1.5 times higher but statistically non-significant in patients receiving sGC stimulators
compared to placebo (RR 1.50, 95%CI: 0.93-2.41, P = 0.10) (Figure 3B). The incidence of
hypotension (RR 1.47, 95%CI: 0.93-2.33, P = 0.10) and syncope (RR 1.18, 95 CI: 0.901.55, P = 0.24) were also numerically higher with the use of sGC stimulator use by 47%
and 18% respectively; however, none of these differences reach the level of statistical
significance. The incidence of anemia was significantly higher in sGC group (RR 1.33,
95%CI: 1.08-1.64, P = 0.007). There was minimal heterogeneity among the studies
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Figure 3 Forest plot for the primary composite endpoint overall side-effects showing an individual and pooled risk ratio for randomized
controlled trials comparing soluble guanylate cyclase stimulators to control. A: Pooled composite endpoint; B: Overall side-effects. The pooled risk
ratio (RR) with 95% confidence interval (CI) were calculated using random-effects models. Weight refers to the contribution of each study to the overall pooled
estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95%CI for each trial’s RR, respectively. The diamonds signify the pooled
RR; the diamond’s centre denotes the point estimate and width denotes the 95%CI. CI: Confidence interval; sGC: Soluble guanylate cyclase.

comparing NAECI and hypotension (I2 = 35% and I2 = 20%, respectively) .
Net clinical benefit: The overall number needed to treat (NNT) for the primary
composite endpoint by adding vericiguat to the standard guideline-directed HF
therapy was 35 (95%CI: 18.7-332.2). The overall number needed to harm (NNH) for
NAECI was 44 (95%CI: 25.2-180). The net clinical benefit (NCB) was 9, indicating
futility. The overall NNT to prevent one death due to any-cause was 142 (95%CI: 36.374.2) and to prevent one death from cardiovascular cause was 111 (95%CI: 35.3-96.7).
None of the NNT values was statistically significant, as evidenced by the cross-over of
its CI with the NNH.

Subgroup sensitivity analysis
A stratified analysis of prespecified subgroups adjusted on the type of HF (HFrEF and
HFpEF) and choice of experimental regimen (vericiguat and riociguat) showed
significant deviation from the pooled results. Two studies comprising 5233 patients
(2616 sGC stimulator and 2617 placebo) contributed to the comparison of vericiguat
and placebo agents in HFrEF patients. In contrast to the pooled results, there was no
significant difference in the incidence of primary composite endpoint between patients
receiving vericiguat and placebo for HFrEF (RR 0.84, 95%CI: 0.58-1.21, P = 0.24).
Similarly, the rate of primary composite endpoint remained identical across patients
on placebo and those receiving riociguat for HFrEF (RR 0.97, 95%CI: 0.54-1.76, P =
0.92) or HFpEF (RR 0.78, 95%CI: 0.24-2.56, P = 0.68) (Supplementary Figure 1).
Compared to placebo, there was no significant difference in the rate of total HF-related
hospitalizations across HFrEF patients receiving vericiguat (RR 0.84, 95%CI: 0.60-1.20,
P = 0.34) or riociguat (RR 0.97, 95%CI: 0.54-1.76, P = 0.92) and HFpEF patients on
riociguat (RR 0.68, 95%CI: 0.18-2.64, P = 0.58) (Supplementary Figure 2).
The incidence of all-cause mortality stratified by the type of sGC stimulators or type
of HF mirrored the overall results. A similar rate of mortality was obtained between
patients on placebo vs those on vericiguat (RR 0.96, 95%CI: 0.86-1.07, P = 0.43) or
riociguat (RR 1.97, 95%CI: 0.32-12.16, P = 0.46) (Supplementary Figure 3). Both HFrEF
(5369 patients, 2648 sGC stimulator and 2685 placebo) and HFpEF (200 patients, 94
sGC stimulator and 106 placebo group) followed the pooled results of all-cause
mortality, showing a similar incidence of mortality between the two groups (RR 0.96,
95%CI: 0.86-1.07, P = 0.44 and RR 1.45, 95%CI: 018-11.54, P = 0.73, respectively) (
Supplementary Figure 4). Sensitivity analysis by the exclusion of PAH-CHD study also
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Figure 4 Forest plot for hospitalizations, cardiovascular and all-cause mortality showing an individual and pooled risk ratio for
randomized controlled trials comparing soluble guanylate cyclase stimulators to control. A: Hospitalizations; B: Cardiovascular; C: All-cause
mortality. CI: Confidence interval; sGC: Soluble guanylate cyclase.

did not alter the results of pooled analysis (RR 0.96, 95%CI: 0.86-1.07, P = 0.45) (
Supplementary Figure 5).

Publication bias
The funnel plot showed asymmetry, indicating the possibility of publication bias.
(Figure 5) The vertical axis of the plot used standard error to estimate the sample size
of the study, plotting large population studies on top and smaller at the bottom. The
horizontal spread reflected the power and effect size of the included studies. One can
argue that it is difficult to differentiate between “findings by chance” and “real
asymmetry,” as only six articles were assessed for potential publication bias. As
pointed by Sterne et al[14]. in a study of fewer than ten articles, it is difficult to ascertain
publication bias.

DISCUSSION
To our knowledge, this is the largest study performed to assess the safety and efficacy
of novel sGC stimulators (vericiguat and riociguat) in patients with HF. The results
were drawn from 6 RCTs, comprising 5604 patients. In the combined analysis, among
patients with high-risk HF (NYHA class II-IV), the addition of sGC stimulators to
current guideline-based medical therapy showed a modest decrease in risk of the
primary composite endpoint (first HF hospitalization plus cardiovascular death) by
8%. With a similar decrease in HF-related total hospitalization by 9%. However, these
benefits were attenuated when the pooled results were matched based on the type of
HF and choice of sGC stimulator. Neither vericiguat nor riociguat groups reached the
threshold of statistical significance when the efficacy endpoints (hospitalization and
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Figure 5 Funnel plot showing possible publication bias. RR: Risk ratio.

death) were stratified by HFrEF and HFpEF. Similarly, compared to the control group,
both vericiguat and riociguat failed to lower the incidence of cardiovascular or allcause mortality, irrespective of the type of HF or duration of follow-up. Moreover, the
incidence of NAECI and its components (hypotension and syncope) in the intervention
group were 1.5 times higher than the placebo group. Briefly, our analysis did not show
the same positive findings seen in the recent VICTORIA trial and highlight the
ambiguity in the use of sGC stimulators, until more definitive evidence is available (
Supplementary Figure 6).
It is interesting to compare our combined results with all included RCTs. The
SOCRATES-PRESERVED and the SOCRATES-REDUCED trials used vericiguat in
patients with HFpEF and HFrEF, respectively[10,11]. These trials were primarily
designed to determine the optimal dose and tolerability of vericiguat. While on pooled
analysis, the relative difference in the NT-proBNP levels was identical, the
SOCRATES-REDUCED did show a significant dose-response relationship. Compared
to placebo, a higher vericiguat dose of 10 mg was associated with greater reductions in
NT-proBNP (P = 0.02) and significant improvement in LVEF (+1.5% vs +3.7%, P = 0.02)
at 3 mo follow-up[11]. Similarly, the SOCRATES-PRESERVED trial showed a substantial
improvement in the functional and symptomatic status of the HFpEF patients
(increase in KCCQ-CSS by more than 5 points) on the 10 mg dose of vericiguat at 3
mo[10]. Both SOCRATES-PRESERVED and REDUCED trials used surrogate markers of
disease severity and were relatively underpowered to gauge hard clinical outcomes
(mortality and hospitalizations).
Three of the included RCTs compared the merits of riociguat against a placebo in
both HFrEF and HFpEF patients. The PATENT-1 (the pulmonary arterial hypertension
sGC-stimulator trial-1) and its long-term extension study PATENT-2 were unique in
terms of inclusion criteria and assessment of outcomes. Riociguat was found to be
associated with a decrease in the mean NT-proBNP levels, improved 6-minute walking
distance (6MWD) and pulmonary vascular resistance (PVR) in patients with PAHCHD[12]. Both LEPHT and DILATE-1 trials demonstrated a significant increase in the
stroke volume (P = 0.001 and P = 0.04) in their respective HFrEF and HFpEF patient
populations. However, there was no significant decrease in the mean pulmonary
arterial pressure (PAP), the primary endpoint, even at the maximally tolerated dose of
riociguat (2 mg)[8,13]. These trials were also underpowered to assess major clinical
endpoints and had variability in dose-response outcomes, limiting their utility.
The more contemporary VICTORIA trial was adequately powered and specifically
designed to measure clinically relevant outcomes[2]. The trial used a cox-regressionmodel to calculate a sample size of 5050 patients, who were hospitalized with the
diagnosis of HFrEF. Both vericiguat and placebo groups in the trial were appropriately
matched, minimizing ascertainment bias, but had a high rate of noncompliance and
loss to follow-up. At a median follow-up of 10 mo, 24% of the vericiguat and 22% of
the placebo arm had discontinued the trial regimen. While this amount of
nonadherence was anticipated and an “intention to treat model” was used to reduce
its impact on the overall results, the pooled difference in the primary composite
endpoint was modest (RR 0.90, 95%CI: 0.82-0.98, P = 0.02). The incidence of
cardiovascular mortality was near identical in the vericiguat and placebo groups
(12.9% vs 13.9%, P = 0.83), indicating that the primary outcome was driven by the
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lower rate of HF-related hospitalization in the vericiguat group (38.3% vs 42.4%, P =
0.02)[2]. By contrast, our pooled analysis of vericiguat in HFrEF population showed no
inter-group difference in both the incidence of the primary composite (P = 0.34),
cardiovascular mortality (P = 0.29), and total HF-related hospitalizations (P = 0.34).
Nonetheless, mirroring our pooled results, the VICTORIA trial showed no significant
difference in the incidence of all-cause mortality between vericiguat and the placebo
groups (20.3% vs 21.2%, P = 0.38). This underscores that the lower hospitalization rate
in the vericiguat arm did not translate into clinical survival benefits. Together, these
findings call for caution while interpreting the findings of the VICTORIA trial.
The present meta-analysis sought to address the overall discrepancies by
systematically adjusting the definition of primary composite outcome and by
excluding patients on the suboptimal dose of sGC stimulators. By design, our study
prevents the influence of both known and unknown confounding factors due to the
inclusion of high-quality studies. Our study showed no clinical benefits of sGC
stimulator in terms of reducing mortality or HF-related hospitalization when the
overall outcomes were stratified by type of HF and regimen of trial medication. These
findings contrast with the most contemporary VICTORIA trial, which showed a
decrease in the incidence of HF-related total hospitalizations and death from
cardiovascular causes. Also unique was a demonstration of the consistent
ineffectiveness of vericiguat and riociguat to reduce all-cause mortality across all
included trials. Moreover, the calculation of the net clinical benefit may serve to inform
clinical decision making, suggesting that sGC stimulators offer no benefits and could
potentially be harmful.

Limitations
Our study is constrained by the limitations of the included studies. Patient-level data
were missing to measure the impact of non-compliance on overall clinical outcomes.
Long term follow-up data was lacking in more than half of the included studies,
limiting our ability to calculate their predictive effects. Some studies focused on nonclinical primary outcomes (pro-BNP, PAP) neglecting a significant amount of clinical
complications such as myocardial infarction and mortality, reducing the precision of
estimated complications. Due to the paucity of long-term follow-up data, it is unclear
if these results could be extrapolated to patients with HFpEF. The ongoing DYNAMIC
study might shed more light on the efficacy of sGC in patients with HFpEF[15].
It can also be argued that the assessment of the efficacy and safety of the sGC
stimulators is a bivariate exercise, and summarizing it in a unidimensional variable
(net clinical benefit) could be misleading. For example, a large number of relatively
minor episodes of hypotension versus a small improvement in HF-related
hospitalization rate may lead to a negative calculated Net Clinical Benefit (NCB). Still,
given the vast disparity between the impact on the quality of life between an episode
of hypotension versus HF-related hospitalization, it may falsely undervalue the benefit
of therapy. Therefore, the NCB value should preferably be interpreted in the context of
the nature of both adverse and beneficial events, without committing to value
judgment. That being said, in our case, we found no significant beneficial effect of sGC
stimulators and a higher incidence of adverse effects rendering this a moot point.

CONCLUSION
Vericiguat and riociguat offer no additional benefits to current guideline-based
medical therapy in terms of reducing the incidence of hospitalization or mortality in
patients with HFpEF or HFrEF. Further larger-scale studies are needed to validate
these findings.

ARTICLE HIGHLIGHTS
Research background
Despite treatment with traditional pharmacologic management, patients with heart
failure (HF) have a dismal prognosis, with approximately 1 million HF-related
hospitalizations (HHF) occurring annually, accounting for over 6.5 million hospital
days and $37.2 billion each year.
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Research motivation
This has led researchers to study the efficacy of alternate drugs in preventing HF
exacerbations, which include soluble guanylate cyclase (sGC) stimulators vericiguat
and riociguat. Multiple clinical trials have attempted to explore the utility of vericiguat
and riociguat in patients with HF. However, there a lack of large scale studies to
determine the true merits of sGC stimulators in patients with HF.

Research objectives
Therefore, we performed this meta-analysis to determine the efficacy and safety of
sGC stimulators in HF patients.

Research methods
The MEDLINE (PubMed, Ovid), Embase, Clinicaltrials.org and Cochrane databases
were queried with various combinations of medical subject headings (MeSH) to
identify relevant articles. All randomized control trials (RCT) until March 31, 2020,
comparing the safety and efficacy of sGC in HF were evaluated for inclusion. The
primary efficacy endpoint was a composite of the first hospitalization for HF and
death from cardiovascular causes. The secondary efficacy endpoints were the
components of the primary outcome, total HF-related hospitalizations, cardiovascular
and all-cause mortality. The statistical analysis was performed using the
Cochran–Mantel–Haenszel test on a random-effect model to calculate relative risk (RR)
for the dichotomous outcomes of RCTs. The overall quality of the included RCTs was
high.

Research results
Six RCTs comprising 5604 patients (2801 sGC stimulator and 2803 placebo) were
included. The primary endpoint (a composite of cardiovascular mortality and first HFrelated hospitalization) was reduced in patients receiving sGC stimulators compared
to placebo [RR 0.92, 95% confidence interval (CI): 0.85-0.99, P = 0.02]. The incidence of
total HF-related hospitalizations were also lower in sGC group (RR 0.91, 95%CI: 0.860.96, P = 0.0009), however, sGC stimulators had no impact on all-cause and
cardiovascular mortality (RR 0.96, 95%CI: 0.86-1.07, P = 0.45) and (RR 0.94, 95%CI:
0.83-1.06, P = 0.29), respectively. The overall safety endpoints (composite of
hypotension and syncope) were also identical between the two groups (RR 1.50,
95%CI: 0.93-2.42, P = 0.10). For the primary composite endpoint, the number needed to
treat was 35, the number needed to harm was -44 and the overall net clinical benefit
was -9.

Research conclusions
Data published in literature revealed no additional benefits to guideline-based medical
therapy in reducing incidence of HF hospitalization and mortality with sGC stimulator
use. Large scale studies are required to determine the efficacy of sGC stimulators in
patients with HF.

Research perspectives
As it is unclear whether sGC stimulators have any additional benefit in improving the
prognosis of HF patients due to a lack of substantial research, large scale studies are
needed to determine their efficacy in reducing HF related hospitalization rates.

ACKNOWLEDGEMENTS
We sincerely thank Dr. Smith D, and Dr. Eisenstaedt R for providing research
opportunities and resources in the institute.

REFERENCES
1

WJC

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M,
Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC,
Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar
DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves
MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano
NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P;

https://www.wjgnet.com

510

October 26, 2020

Volume 12

Issue 10

Ullah W et al. Safety and efficacy of sGC stimulators in heart failure

2

3

4

5

6

7

8

9

10

11

12

13

14

15

WJC

American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke
Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American
Heart Association. Circulation 2018; 137: e67-e492 [PMID: 29386200 DOI:
10.1161/CIR.0000000000000558]
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G,
Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM,
Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of
the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, FunckBrentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner
Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U,
Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P,
Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S,
Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute
and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the
Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869 [PMID: 22828712 DOI:
10.1093/eurjhf/hfs105]
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P,
Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group.
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020; 382: 18831893 [PMID: 32222134 DOI: 10.1056/NEJMoa1915928]
Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL,
Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-Velten G, McMurray JJV. Effect of
sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine
Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2018;
20: 760-768 [PMID: 29431251 DOI: 10.1002/ejhf.1139]
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon
SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin
inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004 [PMID: 25176015 DOI:
10.1056/NEJMoa1409077]
Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A. Cinaciguat,
a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated
heart failure. Eur Heart J 2013; 34: 57-67 [PMID: 22778174 DOI: 10.1093/eurheartj/ehs196]
Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, BeckerPelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH,
Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trübel H, Sandner P, Stasch JP. Discovery of the
Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart
Failure. J Med Chem 2017; 60: 5146-5161 [PMID: 28557445 DOI: 10.1021/acs.jmedchem.7b00449]
Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise
AV, Roessig L, Semigran MJ; Left Ventricular Systolic Dysfunction Associated With Pulmonary
Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension
caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled,
dose-ranging hemodynamic study. Circulation 2013; 128: 502-511 [PMID: 23775260 DOI:
10.1161/CIRCULATIONAHA.113.001458]
Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in
cardiopulmonary disease. Circulation 2011; 123: 2263-2273 [PMID: 21606405 DOI:
10.1161/CIRCULATIONAHA.110.981738]
Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ,
Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M. Vericiguat in patients with worsening
chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in
heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 2017; 38:
1119-1127 [PMID: 28369340 DOI: 10.1093/eurheartj/ehw593]
Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ,
Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED
Investigators and Coordinators. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic
Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The
SOCRATES-REDUCED Randomized Trial. JAMA 2015; 314: 2251-2262 [PMID: 26547357 DOI:
10.1001/jama.2015.15734]
Rosenkranz S, Ghofrani HA, Beghetti M, Ivy D, Frey R, Fritsch A, Weimann G, Saleh S, Apitz C.
Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 2015; 101:
1792-1799 [PMID: 26135803 DOI: 10.1136/heartjnl-2015-307832]
Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, Bojic A, Lam CSP,
Frey R, Ochan Kilama M, Unger S, Roessig L, Lang IM. Acute hemodynamic effects of riociguat in patients
with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, doubleblind, placebo-controlled, single-dose study. Chest 2014; 146: 1274-1285 [PMID: 24991733 DOI:
10.1378/chest.14-0106]
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid
CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP.
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised
controlled trials. BMJ 2011; 343: d4002 [PMID: 21784880 DOI: 10.1136/bmj.d4002]
Mascherbauer J, Grünig E, Halank M, Hohenforst-Schmidt W, Kammerlander AA, Pretsch I, SteringerMascherbauer R, Ulrich S, Lang IM, Wargenau M, Frey R, Bonderman D. Evaluation of the
pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with

https://www.wjgnet.com

511

October 26, 2020

Volume 12

Issue 10

Ullah W et al. Safety and efficacy of sGC stimulators in heart failure
preserved ejection fraction : Study protocol for a randomized controlled trial. Wien Klin Wochenschr 2016;
128: 882-889 [PMID: 27590259 DOI: 10.1007/s00508-016-1068-8]

WJC

https://www.wjgnet.com

512

October 26, 2020

Volume 12

Issue 10

Published by Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com

© 2020 Baishideng Publishing Group Inc. All rights reserved.

